Related Experiment Video

Updated: Jun 10, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Bleomycin revisited: towards a more representative model of IPF?

Chris J Scotton, Rachel C Chambers

    American Journal of Physiology. Lung Cellular and Molecular Physiology
    |August 3, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
    05:45

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

    Published on: January 16, 2026

    Related Experiment Videos

    Last Updated: Jun 10, 2026

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
    05:45

    A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

    Published on: January 16, 2026

    Related Concept Videos

    Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

    Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

    Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
    Chronic Obstructive Pulmonary Disease II: Emphysema01:23

    Chronic Obstructive Pulmonary Disease II: Emphysema

    Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

    Articles linked to this work by shared authors, journal, and citation graph.

    Protocol for the INterstitial lung Disease EXacerbations (INDEX) Study: a retrospective multicentre cohort study.

    BMJ open respiratory research·2026

    Polygenic risk and rare variants in endotypes of idiopathic pulmonary fibrosis: a genetic analysis of population-based and case-control cohorts.

    The Lancet. Respiratory medicine·2026

    Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.

    EBioMedicine·2026

    Utilisation of cardiopulmonary exercise testing for tailored pulmonary rehabilitation in people with interstitial lung diseases: A systematic review.

    Clinical rehabilitation·2025

    Imaging technologies in experimental pulmonary fibrosis research: essential tool for enhanced translational relevance.

    European respiratory review : an official journal of the European Respiratory Society·2025

    Exploring the potential of cardiopulmonary exercise testing (CPET) for tailored pulmonary rehabilitation in people with interstitial lung disease (ILD): A systematic review protocol.

    NIHR open research·2025

    MicroRNAs in IPF and Lung Cancer: Convergent and Divergent Mechanisms: a systematic review.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Mechanical and Chemical Power and Mortality in Acute Respiratory Distress Syndrome: An Exploratory Analysis of Six Patient Cohorts.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Testosterone alleviates inflammation but increases the methacholine response in male mice with allergic lung inflammation.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Conversations in Collagen: Multicellular Crosstalk Shapes the Fibrotic Niche in Pulmonary Fibrosis.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Central Cholinergic Modulation of the Cough Reflex: Suppressive Effects of Donepezil in rabbits.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Efficient AI-supported quantification of network structures in SEM imaged human mucus: A detailed protocol.

    American journal of physiology. Lung cellular and molecular physiology·2026

    Blinatumomab administration in the outpatient setting: Safety and health care utilization.

    Cancer·2026

    Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

    Rheumatology (Oxford, England)·2026

    The Role of γδ T Cells in Ischemic Stroke: Insights From the Perspective of the Brain-Gut Axis.

    CNS neuroscience & therapeutics·2026

    Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy.

    Haematologica·2026

    Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

    Haematologica·2026

    Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin's lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.

    Haematologica·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us